- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00272090
Insulin Glargine in Type 1 Diabetes Mellitus
June 7, 2011 updated by: Sanofi
Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients.
The primary purpose of the protocol is to demonstrate that the new regimen (insulin glargine+regular insulin ) is no worse than the reference regimen (insulin glargine+lys-pro insulin ) in reducing the incidence of severe nocturnal hypoglycemia at the end point; the secondary purpose is to compare the two study regimens as far as the glycemic control (measured by HbA1c), the daily Mean Blood Glucose (MBG) and the mean amplitude of glycemic excursion (MAGE index), calculated on the basis of Self Monitoring Blood Glugose (SMBG) data, are concerned and to verify the safety of basal insulinization with Lantus.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
489
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Subjects with type 1 diabetes mellitus for more than three years
- Subjects on multiple daily injection insulin therapy, basal-bolus scheme therapy
- HbA1c <= 9 % (measured by central Lab, with DCCT aligned standard method)
- Fasting C-Peptide <= 0,1nmol/L with FBG >126 mg/dl
- Body Mass Index (BMI) < 30 kg/m2
- Willingness to accept intensive insulin therapy
- Ability and willingness to perform SMBG using plasma glucose meter
- Female subjects must be postmenopausal or under adequate contraception as judged by the investigator (it may be oral contraceptives, intra-uterine device or surgical treatment) and must have a negative serum pregnancy test
Exclusion criteria:
- Diabetes other than type 1 diabetic mellitus
- Type 1 diabetic patients with total insulin dose >= 1 IU/kg/day
- Serum creatinine > 1.5 mg/dl, or history of renal transplantation or current renal dialysis
- Congestive heart failure NYHA class II
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Clinical evidence of active liver disease, or serum ALT/AST 2 times the upper limit of the normal range
- Hypoglycemia unawareness
- Pregnancy or lactation
- Concomitant use of β-blockers, thiazides or systemic corticosteroids
- More than one episode of severe hypoglycemia with seizure or coma during the past year
- Likelihood of requiring treatment during the study period with any anti-diabetic drug other than the study drugs
- Failure to use adequate contraception (women of current reproductive potential only)
- Known hypersensitivity to insulin glargine, or any of the excipients
- Malignancy except basal cell carcinoma within the last five years
- Long lasting (> 2 weeks) treatment with systemic glucocorticoid therapy
- Known adrenal insufficiency (interferes with hypoglycemia counter-regulation)
- Known hemoglobinopathy or chronic anemia because it may interfere with Hb1Ac determination
- History of substance or alcohol abuse within the last two years or current addiction to substances of abuse including ethanol
- History of positive HIV test or Hepatitis B/C test
- Any usage outside of the current SPC (Summary of the Product Characteristics)
- Any clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease other than type 1 diabetic mellitus making implementation of the protocol or interpretation of the study results difficult
- History of demonstrable micro- and macro-angiopathic complications
- Pre-planned surgery during the study
- Blood donation of more than 500 ml during the previous 3 months for males or 6 months for females
- Smoker for previous 3 months
- Receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
severe nocturnal hypoglycemias will be measured throughout the study period.
|
Secondary Outcome Measures
Outcome Measure |
---|
HbA1c will be measured at basal and 8/16 weeks after start of treatment
|
8 point glucose profile will be measured during last 2 weeks before each scheduled visit
|
severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2002
Primary Completion (Actual)
December 1, 2005
Study Completion (Actual)
December 1, 2005
Study Registration Dates
First Submitted
January 2, 2006
First Submitted That Met QC Criteria
January 2, 2006
First Posted (Estimate)
January 4, 2006
Study Record Updates
Last Update Posted (Estimate)
June 8, 2011
Last Update Submitted That Met QC Criteria
June 7, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOE901_3507
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Insulin glargine
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
-
SanofiCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
IRCCS San RaffaeleTerminatedType 2 Diabetes Mellitus | Peripheral Vascular DiseaseItaly
-
SanofiCompleted
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
Medical University of GrazCompletedDiabetes Mellitus, Type 2Austria
-
SanofiCompletedType 1 Diabetes MellitusJapan